Biodesix

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Boulder, CO.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biodesix reports robust Q4 revenue growth and expands reimbursement coverage

Biodesix's strong revenue growth and progress in reimbursement coverage underscore its position in the lung diagnostic testing market.
Continued success with newer tests like Nodify XL2 and Nodify CDT presents opportunities for further expansion and increased payer acceptance.

Biodesix reports robust Q1 revenue growth amidst operational challenges

Biodesix's Q1 2023 performance reflects strong revenue growth driven by core lung diagnostics and test volume expansion.
While facing challenges such as increased operating expenses and delayed clinical trials, the company maintains a focus on growth.
Opportunities lie in leveraging their precision tests portfolio, revenue diversification, and strategic investments for future growth.

Biodesix reports robust Q2 earnings, eyes sustained growth trajectory

Biodesix's Q2 2023 performance reflects strong revenue growth and improved margins, driven by core lung diagnostic tests.
While facing challenges in revenue diversification and cost management, the company's focus on clinical utility and growth opportunities remains promising.
With upcoming conference presentations and investor support, Biodesix is poised to sustain growth and advance towards profitability.

Biodesix reports robust Q3 earnings and strategic growth initiatives

Biodesix delivered a strong Q3 performance with revenue growth, improved margins, and cost management.
The company faces challenges in study timelines and commercialization but has opportunities in market expansion and product development.
By focusing on sales force expansion, quality culture, and cost control, Biodesix is positioning itself for future success.
Investors should note the company's resilience, growth potential, and strategic focus on profitability and market expansion.

Biodesix reports robust 2023 performance, eyes sustained growth in 2024

Biodesix's strong 2023 performance in revenue growth and margin improvement sets the stage for sustained growth in 2024.
The company's focus on operational efficiency, market expansion, and test adoption positions it well for future success.
Challenges in sustaining growth momentum and managing costs are balanced by opportunities in market penetration and profitability.
Investments in sales expansion and ongoing clinical studies present avenues for continued growth and innovation in the coming year.

Biodesix reports robust Q1 performance, focuses on growth strategies

Biodesix's Q1 2024 performance reflects strong revenue growth and operational achievements, despite a net loss.
Strategic partnerships and financial initiatives position the company well for future growth and innovation.
Addressing profitability challenges and operational efficiency will be key for Biodesix's sustained success in the competitive healthcare market.

Biodesix reports robust Q2 growth, raises revenue guidance for 2024

Biodesix's Q2 2024 performance reflects strong revenue growth and operational improvements, despite some profitability challenges.
The company's focus on innovation in lung cancer care and positive workplace culture position it well for future success.
With increased revenue guidance, expanding market opportunities, and a commitment to impact healthcare, Biodesix shows promise for continued growth.

Biodesix reports robust Q3 performance amidst revenue growth challenges

Biodesix demonstrated strong financial performance in Q3 2024 with revenue growth, improved margins, and a focus on innovation.
While facing challenges in biopharma services revenue and operational disruptions, the company remains resilient and proactive.
Opportunities lie in revenue growth through lung volume increase, addressing payment issues, and expanding sales team effectiveness.
Overall, Biodesix's strategic focus on growth and efficiency positions it well for future success in the diagnostics market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Louisville, CO.

LOUISVILLE, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions and services company, today provided a corporate update and announced its financial and operating results for the fourth quarter and year ended December 31, 2023 (fiscal 2023). “I am exceptionally proud of the Biodesix team and our record of accomplishments in 2023,” said Scott Hutton, CEO of Biodesix. “We were focused on three goals: driving increased revenue through adoption of our Lung Diagnosti.

Biodesix Announces Fourth Quarter and Fiscal Year 2023 Results and Business Highlights

LOUISVILLE, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today that Scott Hutton, Chief Executive Officer of Biodesix, will present and host in-person 1x1 investor meetings at the TD Cowen 44th Annual Health Care Conference, which will be held from March 4-6, 2024. TD Cowen 44th Annual Health Care Conference Presentation Date: Monday, March 4, 2024 Presentation Time: 10:30 AM ET Location: Marriot Copley Pla.

Biodesix to Participate in the TD Cowen 44th Annual Health Care Conference

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today that it will release financial results for the fourth quarter and year ended December 31, 2023 before the open of trading on Friday, March 1. Biodesix's management will host a conference call and webcast to discuss its financial results and provide a general business update at 8:30 a.m. Eastern Time on the same day. Listeners can register for the w.

Biodesix to Report Fourth Quarter and Full Year 2023 Financial Results on March 1, 2024

Powerbridge Technologies Co Ltd

VistaGen Therapeutics

Despite the recent economic deceleration, positive factors like a tight labor market and strong consumer spending support a resilient U.S. economy. Goldman Sachs predicts increased state and local government spending, and overall expectations suggest that, while there may be a short slowdown, the U.S. economy is anticipated to remain on a positive trajectory in 2024.

3 Penny Stocks to Turn $999 Into $1 Million: January 2024

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today the validation and launch of a new method of collecting blood specimens for Nodify Lung Nodule Risk Assessment testing. The method uses the FDA-cleared Tasso+™ device, a single-use blood lancing device intended for obtaining capillary whole blood samples from a patient's upper arm. Blood-based Nodify Lung testing, comprised of the Nodify CDT® and N.

Biodesix Enhances Access to Nodify Lung® Testing with Launch of New Blood Draw Method

Biodesix, Inc. (NASDAQ:BDSX ) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Chris Brinzey - Investor Relations Scott Hutton - Chief Executive Officer Robin Harper Cowie - Chief Financial Officer Conference Call Participants Dustin Scaringe - William Blair Kyle Mikson - Canaccord Genuity Operator Good day and thank you for standing by. Welcome to the Biodesix Quarter Three 2023 Earnings Conference Call.

Biodesix, Inc. (BDSX) Q3 2023 Earnings Call Transcript

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer, will participate in two upcoming investor conferences: Canaccord Genuity Medtech, Diagnostics, Digital Health & Services Forum Presentation and 1x1 Meetings Presentation Date and Time: Thursday, November 16, 2023 at 3:00 PM ET Location: Westin NY Grand Central, New York, NY Piper Sandler 35th Annual Health.

Biodesix to Participate in Two Upcoming Investor Conferences in November

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced its financial and operating results for the third quarter ended September 30, 2023 and provided a corporate update. “I am pleased to announce yet another impressive quarter of growth at Biodesix,” said Scott Hutton, President and Chief Executive Officer. “The team delivered over 10,400 Lung Diagnostics tests, growing 60% over the 6,500 tests delive.

Biodesix Announces Third Quarter 2023 Results and Highlights

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus on lung disease, announced today that it will release financial results for the third quarter ended September 30, 2023 after the close of trading on Tuesday, November 7. Biodesix's management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. Listeners can register for the webcas.

Biodesix to Report Third Quarter 2023 Financial Results on November 7, 2023

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that new data will be presented at the CHEST Annual Meeting 2023 in Honolulu, Hawaiʻi. These presentations will provide new insight on the clinical utility and real-world impact of the Nodify CDT and Nodify XL2 tests in the comprehensive management of lung nodules. The first abstract, titled "Real-World Impact of a Blood-Based Integrated Classifier.

Biodesix to Present New Data on Nodify Lung® Testing at CHEST 2023 Annual Meeting

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that two abstracts will be presented at the International Association for the Study of Lung Cancer (IASLC) 2023 World Lung Conference on Lung Cancer (WCLC). The first presentation showcases a new analysis of the large multi-center observational registry study INSIGHT (Clinical Effectiveness Assessment of VeriStrat® Testing and Validatio.

Biodesix Announces Two Presentations on Lung Cancer Treatment Guidance Tests at the IASLC 2023 World Lung Conference on Lung Cancer

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will participate in two upcoming investor conferences: Morgan Stanley 21st Annual Global Healthcare Conference Fireside Chat and 1x1 Meetings Fireside Date: Tuesday, September 12, 2023 Fireside Time: 12:15 PM ET Location: Sheraton Hotel, New York, NY H.C. Wainwright 25th Annual Global I.

Biodesix to Participate in Two Upcoming Investor Conferences in September

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that a new analysis from the post-market, prospective, real-world ORACLE study (An Observational Registry Study to Evaluate the Performance of the Nodify XL2 Test NCT03766958) will be presented at the 6th Annual Conference of the American Association for Bronchology and Interventional Pulmonology (AABIP). The data will be presented by p.

Biodesix Announces Presentation of New Nodify XL2® Data at AABIP Conference Highlighting Increased Proportion of Biopsies Diagnosing Cancer

Biodesix, Inc. (NASDAQ:BDSX ) Q2 2023 Earnings Conference Call August 7, 2023 4:30 PM ET Company Participants Chris Brinzey - Investor Relations Scott Hutton - Chief Executive Officer Robin Harper Cowie - Chief Financial Officer Conference Call Participants Maggie Boeye - William Blair Kyle Mikson - Canaccord Genuity Yuko Oku - Morgan Stanley Operator Good day and thank you for standing by. Welcome to the Biodesix Second Quarter 2023 Earnings Conference Call.

Biodesix, Inc. (BDSX) Q2 2023 Earnings Call Transcript

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced its financial and operating results for the second quarter ended June 30, 2023 and provided a corporate update “I am very pleased to announce another record-setting quarter from our core lung diagnostics,” said Scott Hutton, President and Chief Executive Officer. “In addition to continued sales growth, we had a number of important publi.

Biodesix Announces Second Quarter 2023 Results and Highlights

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that Scott Hutton, Chief Executive Officer of Biodesix, will present and host in-person 1x1 investor meetings at the Canaccord Genuity 43rd Annual Growth Conference, which will be held from August 7-10, 2023. Canaccord Genuity 43rd Annual Growth Conference Fireside Chat Date: Wednesday, August 9, 2023 Fireside Chat Time: 4:00 PM ET Loca.

Biodesix to Participate in the Canaccord Genuity 43rd Annual Growth Conference

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus on lung disease, announced today that it will release financial results for the second quarter ended June 30, 2023 after the close of trading on Monday, August 7. Biodesix's management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. Listeners can register for the w.

Biodesix to Report Second Quarter 2023 Financial Results on August 7, 2023

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that the prospective, real-world ORACLE study (An Observational Registry Study to Evaluate the Performance of the Nodify XL2® Test [NCT03766958]) achieved the primary endpoint of a statistically significant change in the proportion of benign lung nodules managed by Nodify XL2® experiencing invasive procedures. The data was published in.

Biodesix Announces Publication of the ORACLE Clinical Utility Study with the Primary Endpoint Demonstrating that the Nodify XL2® Test Reduced Unnecessary Invasive Procedures on Benign Lung Nodules

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that the Centers for Medicare & Medicaid Services (CMS) has designated the Nodify CDT® Test as an Advanced Diagnostic Laboratory Test (ADLT) effective June 30, 2023. Obtaining ADLT status is a recognition that the Nodify CDT test meets the stringent criteria established under the Protecting Access to Medicare Act of 2014 (PAMA). ADL.

Biodesix Awarded Advanced Diagnostic Laboratory Test Status for its Nodify CDT® Test by the Center for Medicare and Medicaid Services

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that the large multi-center observational registry study INSIGHT (Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects) (NCT03289780) has completed enrollment of 5,000 patients with non-small cell lung cancer (NSCLC). The study was designed to further validate the utility of the.

Biodesix Completes Enrollment of INSIGHT Study Assessing Clinical Utility of the VeriStrat® Blood-Based Host Immune Classifier

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that three new scientific abstracts will be presented as part of the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting including a poster presented by Friends of Cancer Research (FoCR) featuring genomic data contributed by Biodesix and other organizations. This poster highlights long term patient outcomes from the ctMoniT.

Biodesix Announces Three Abstracts to Be Presented at ASCO 2023 Annual Meeting

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that Scott Hutton, Chief Executive Officer of Biodesix, will present and host in-person 1x1 investor meetings at William Blair's 43rd Annual Growth Stock Conference, which will be held from June 6-8, 2023. William Blair's 43rd Annual Growth Stock Conference Presentation Date: Wednesday, June 7, 2023 Presentation Time: 4:40 PM CT Locatio.

Biodesix to Participate in William Blair's 43rd Annual Growth Stock Conference

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, presented original data in four separate poster presentations at the ISPOR (International Society for Pharmaceutical and Outcomes Research) conference, providing evidence of the health economic benefits of the Nodify CDT® and Nodify XL2® tests in the management of pulmonary nodules. The posters, presented May 8-9, 2023, highlighted potential cost savin.

Biodesix Announces Four Presentations of Health Economic Data Highlighting Cost Saving Potential of Nodify Lung® Testing

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. a leading diagnostics company, is proud to announce that its Chief Financial Officer, Robin Harper Cowie, has been appointed to the Colorado BioScience Association (CBSA) board of directors. As a seasoned executive with extensive experience in the life sciences sector, Ms. Harper Cowie's expertise will play a crucial role in driving the growth and development of Colorado's thriving life sciences community. In joining the CBSA board, Ms. Harper Cow.

Biodesix, Inc. Chief Financial Officer Robin Harper Cowie Appointed to Colorado BioScience Association's Board of Directors

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announces new clinical utility data highlighting the impact of the Nodify XL2 Risk Assessment Test on clinical management decisions in patients with lung nodules will be presented at the American Thoracic Society (ATS) 2023 International Conference. The meeting will take place May 19-24, 2023, in Washington, DC. Data from the abstract titled, Assessmen.

News for Biodesix Stock (BDSX)